Discovery of a potent, orally bioavailable and highly selective human neuronal nitric oxide synthase (nNOS) inhibitor, N-(1-(piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide as a pre-clinical development candidate for the treatment of migraine

Subhash C. Annedi, Shawn P. Maddaford, Jailall Ramnauth, Paul Renton, Taras Rybak, Sarah Silverman, Suman Rakhit, Gabriela Mladenova, Peter Dove, John S. Andrews, Dongqin Zhang, Frank Porreca

Open source

DOI: 10.1016/j.ejmech.2012.07.006
Published: 2012-09
Container: European Journal of Medicinal Chemistry
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejmech.2012.07.006,
  title = {Discovery of a potent, orally bioavailable and highly selective human neuronal nitric oxide synthase (nNOS) inhibitor, N-(1-(piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide as a pre-clinical development candidate for the treatment of migraine},
  author = {Subhash C. Annedi and Shawn P. Maddaford and Jailall Ramnauth and Paul Renton and Taras Rybak and Sarah Silverman and Suman Rakhit and Gabriela Mladenova and Peter Dove and John S. Andrews and Dongqin Zhang and Frank Porreca},
  year = {2012},
  journal = {European Journal of Medicinal Chemistry},
  doi = {10.1016/j.ejmech.2012.07.006},
  url = {https://doi.org/10.1016/j.ejmech.2012.07.006}
}

RIS

TY  - JOUR
TI  - Discovery of a potent, orally bioavailable and highly selective human neuronal nitric oxide synthase (nNOS) inhibitor, N-(1-(piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide as a pre-clinical development candidate for the treatment of migraine
AU  - Subhash C. Annedi
AU  - Shawn P. Maddaford
AU  - Jailall Ramnauth
AU  - Paul Renton
AU  - Taras Rybak
AU  - Sarah Silverman
AU  - Suman Rakhit
AU  - Gabriela Mladenova
AU  - Peter Dove
AU  - John S. Andrews
AU  - Dongqin Zhang
AU  - Frank Porreca
PY  - 2012
JO  - European Journal of Medicinal Chemistry
DO  - 10.1016/j.ejmech.2012.07.006
UR  - https://doi.org/10.1016/j.ejmech.2012.07.006
ER  -

APA

Annedi, S. C., Maddaford, S. P., Ramnauth, J., Renton, P., Rybak, T., Silverman, S., Rakhit, S., Mladenova, G., Dove, P., Andrews, J. S., Zhang, D., & Porreca, F. (2012). Discovery of a potent, orally bioavailable and highly selective human neuronal nitric oxide synthase (nNOS) inhibitor, N-(1-(piperidin-4-yl)indolin-5-yl)thiophene-2-carboximidamide as a pre-clinical development candidate for the treatment of migraine. European Journal of Medicinal Chemistry. https://doi.org/10.1016/j.ejmech.2012.07.006

Source records

crossref · retrieved 2026-09-26T04:38:01.312Z